Virtual screening of approved drugs against purine nucleoside phosphorylase of Schistosoma mansoni
by M. Rama; N.V. Anil Kumar; S. Balaji
International Journal of Computational Biology and Drug Design (IJCBDD), Vol. 8, No. 4, 2015

Abstract: Schistosomiasis is an endemic neglected tropical disease caused by trematodes of the genus Schistosoma. Purine nucleoside phosphorylase (PNP) of purine salvage pathway is essential for recovery of nucleosides in Schistosoma species. Schistosoma mansoni PNP (SmPNP) is well-explored drug target for schistosomiasis. The currently available drugs have adverse effects such as abdominal discomfort, nausea, drowsiness and pyrexia. Hence, there is a need for new compounds exhibiting anti-schistosomal activity with minimal or no side effects. In the present study, virtual screening of approved drugs from Drug Bank was compared against Schistosoma mansoni and human PNPs. Among the approved drugs, 15 molecules were selected based on the interaction scores, out of which 11 drugs interacted with SmPNP and the remaining four interacted with human PNP.

Online publication date: Tue, 15-Dec-2015

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Computational Biology and Drug Design (IJCBDD):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com